Tim Worden and Matthew Royle discuss the impact of Brexit on the life sciences sector and the possible models that could be followed when renegotiating the UK's relationship with the EU.
A legal toolkit for life sciences companies and their investors providing access to information on:
The German Federal Court of Justice's landmark decision in Eli Lilly v Actavis clarifies the German doctrine of equivalence and impacts on the scope of protection for Swiss-type claims. read more
The High Court has ruled that a generic applicant can rely on bridging data submitted by a different applicant to support an earlier application under Article 10 of Directive 2001/83/EC. read more
The UK's recent vote to leave the EU raises the question of whether the EMA can stay where it currently is.... read more
James Marshall discusses the English Court of Appeal's approach to damages in respect of sales of products derived.... read more
Receive our monthly newsletter keeping you updated on recent developments and events in the Life Sciences sector...